Every 10-Q that IGC Pharma, Inc. (IGC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IGC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IGC filings page.
IGC Pharma, Inc. is a clinical-stage biotechnology company focused on Alzheimer’s disease, led by IGC-AD1, which is in the CALMA Phase 2 trial for agitation in Alzheimer’s dementia. As of June 30, 2026, CALMA had reached its target enrollment of 146 randomized participants, with limited over-enrollment and follow-up continuing before database lock and topline analysis. The company is also developing earlier-stage Alzheimer’s candidates such as TGR-63 and AI-enabled platforms MINT-AD and AHA, all still in development and not approved as diagnostic or therapeutic products.
For the quarter ended June 30, 2026, revenue was $265 thousand (down from $328 thousand) and the net loss was $2.94 million, or $0.03 per share. For the six-month period, revenue was $582 thousand and the net loss was $5.34 million, reflecting higher selling, general and administrative expenses and increased research and development spending on IGC-AD1 and TGR-63. Gross margin contracted to about 18% as the company transitions to third-party manufacturing and maintains a small, non-core wellness and white-label revenue base.
As of June 30, 2026, total assets were $9.50 million, including $5.51 million of intangible assets and $2.07 million of property, plant, and equipment. Cash and cash equivalents were $331 thousand, with a working capital deficit of about $2.0 million and total debt of roughly $1.08 million, mainly from the SBA, Vanquish Funding Group, and FirstFire. Management raised about $1.1 million from equity and $1.3 million from debt in the first half and subsequently added $687 thousand through an at-the-market program. The company has a $12 million revolving credit facility with O-Bank, undrawn as of June 30, 2026, and estimates that existing cash, investments, anticipated financings, and access to this facility will support operations for at least 12 months, though this depends on market and contractual conditions.
IGC Pharma, Inc. reports results for the quarter ended March 31, 2026, as it advances its Alzheimer’s pipeline and AI platforms. Revenue was $317 thousand, slightly below $330 thousand a year earlier, and still comes mainly from life sciences wellness and white‑label products rather than drug sales. The company posted a net loss of $2.4 million, double the $1.2 million loss in the prior-year quarter, driven by higher R&D spending on the Phase 2 CALMA trial of IGC-AD1 and increased stock-based compensation. Cash and cash equivalents fell to $207 thousand, with a working capital deficit of $1.7 million, partly mitigated by $710 thousand of new equity and debt financing, a $12 million credit facility, and cost actions including the sale of a loss-making facility. Management expects continued operating losses while focusing on completing the CALMA trial, developing the MINT-AD AI platform, and progressing additional Alzheimer’s candidates.
IGC Pharma filed its quarterly report for the period ended September 30, 2025. The company reported revenue of $191 thousand for the quarter and a net loss of $1.821 million. R&D expenses rose to $1.588 million as the Phase 2 trial of IGC‑AD1 advanced past the 50% enrollment mark.
Other income was $1.078 million, reflecting a gain from the sale of assets at the Vancouver, Washington facility. The transaction delivered approximately $2.7 million in consideration versus about $1.5 million of carrying value, and included preferential supply rights and a contingent 10% interest on a potential future sale by the buyer.
Cash and cash equivalents were $1.105 million at September 30, 2025, with working capital of $490 thousand. The company amended and extended its $12 million credit facility, reducing the annual facility fee and setting interest at the certificate of deposit rate plus a 1.2% margin. For the six months, revenue was $519 thousand and net cash used in operations was $3.497 million. Common shares outstanding were 91,959,112 as of September 30, 2025.